ALECNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Alector, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$1.95+0.11 (+5.98%)

Close on Oct 19, 2026

Market cap: $216.89M
P/E (TTM): –
Dividend yield: –

Dividends

Alector has not reported a dividend

No dividend per share appears in Alector's annual filings since fiscal 2016.

Where these numbers come from

Parsed from the XBRL in Alector's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ALEC.

Revenue growth-82.9% · median -19.1%

Operating margin-912.4% · median -340.1%

Net margin-850.1% · median -301.0%

Company	Revenue	Growth
CCCC	$35.04M	+2.3%
SGMOQ	$34.56M	-45.8%
VYGR	$34.46M	-19.1%
ACOG	$15.26M	–
ALEC	$13.86M	-82.9%
ACIU	CHF 3.94M	–

Company

Next earnings (est.): Nov 5, 2026, after close
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 103
Held by institutions: 85.8%
Auditor: Ernst & Young LLP
SEC CIK: 1653087

Advertisement
300 × 250